Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04050124 · ClinicalTrials.gov registry record · NA
Impact of Prisma on Donor Site Pain
A NA study of Skin Graft Disorder and Donor Site Complication, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT04050124 is a NA study of Skin Graft Disorder and Donor Site Complication that has completed, run by NYU Langone Health. The registered enrollment target is 17 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04050124, a NA study of Skin Graft Disorder and Donor Site Complication, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the feasibility of evaluating the use of a composite collagen, silver-oxidized regenerated cellulose matrix compared to the standard of care dressing on donor site pain for patients undergoing split-thickness skin grafting in preparation for a larger study.
Conditions Studied
Interventions
- DEVICE Promogran Prisma
- DEVICE Standard of care (SOC) dressings
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-11-07 |
| Est. Completion | 2021-11-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04050124
The ClinicalTrials.gov registry entry for NCT04050124 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Skin Graft Disorder appearing as the primary indexed condition, and to 2 interventions - of which Promogran Prisma is the first listed.
NCT04050124 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04050124 about?
NCT04050124 is a clinical study titled "Impact of Prisma on Donor Site Pain". The purpose of this study is to assess the feasibility of evaluating the use of a composite collagen, silver-oxidized regenerated cellulose matrix compared to the standard of care dressing on donor site pain for patients undergoing split-thickness skin grafting in preparation for a larger study.
What is the current status of trial NCT04050124?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2019-11-07. Estimated completion is 2021-11-29.
What conditions does trial NCT04050124 study?
This clinical trial studies the following conditions: Skin Graft Disorder, Donor Site Complication.
What interventions are being tested in trial NCT04050124?
The interventions under investigation include: Promogran Prisma (DEVICE), Standard of care (SOC) dressings (DEVICE).
Who is sponsoring clinical trial NCT04050124?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04050124 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.